Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190)

Market Cap	6.75B -21.3%
Revenue (ttm)	1.39B +34.4%
Net Income	351.98M +99.8%
EPS	1.10 +105.5%
Shares Out	331.33M
PE Ratio	18.47
Forward PE	15.91
Dividend	0.26 (1.20%)
Ex-Dividend Date	May 27, 2026

Volume	850,000
Open	20.10
Previous Close	20.36
Day's Range	20.10 - 20.10
52-Week Range	17.10 - 28.00
Beta	0.31
Analysts	Strong Buy
Price Target	31.22 (+55.32%)
Earnings Date	Aug 20, 2026

About HKG:2190

Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices in the People’s Republic of China and internationally. It offers a neurovascular product portfolio that covers a suite of products for various categories, including ischemic stroke, hemorrhagic stroke, intracranial stenosis, carotid artery, and intracranial access devices. The company’s peripheral-vascular interventional product portfolio includes stents, balloons, catheters, and filters, as well as cove...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2012
• Employees: 1,214
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2190

Financial Performance

In 2025, HKG:2190's revenue was 1.06 billion, an increase of 35.15% compared to the previous year's 782.48 million. Earnings were 244.37 million, an increase of 143.75%.

Financial numbers in CNY

Analyst Summary

According to 5 analysts, the average rating for 2190 stock is "Strong Buy." The 12-month stock price target is $31.22, which is an increase of 55.32% from the latest price.

Price Target

$31.22

(55.32% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 11, 2026

Data Sources Report a data error